Ravi A. Madan, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 13N240B
- Bethesda, MD 20892
- 301-480-7168
- 301-480-8867
- madanr@mail.nih.gov
RESEARCH SUMMARY
Dr. Madan's clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. Currently, Dr. Madan is investigating the potential of immunocytokines in prostate cancer.
In addition, Dr. Madan is also evaluating treatments in patients with early recurrence of prostate cancer after definitive surgery or radiation (e.g. biochemical recurrence). These clinical trials include interventions such as immunotherapy, radiopharmaceuticals, and anti- androgens, but spare the use of testosterone lowering therapy (i.e. androgen deprivation therapy). Dr. Madan is also the program director of CCR's Physician-Scientist Early Investigator Program.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Ravi A. Madan, M.D.
Clinical Trials
Publications
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations
Biography
Ravi A. Madan, M.D.
Dr. Madan is a Senior Clinician at the National Cancer Institute (NCI), conducting clinical research in prostate cancer with a focus on immunotherapy strategies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. In 2009 he was retained on staff as an assistant clinical investigator. In 2014 he was made the clinical director of the Genitourinary Malignancies Branch and in 2018 he became a Senior Clinician. He holds a joint appointment in the Laboratory of Tumor Immunology and Biology which forms the basis for many of his clinical collaborations. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
Job Vacancies
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
